DWN12088 Fares Well in Study of Healthy Volunteers

DWN12088 Fares Well in Study of Healthy Volunteers

295114

DWN12088 Fares Well in Study of Healthy Volunteers

DWN12088, an investigational therapy for idiopathic pulmonary fibrosis (IPF), showed promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase 1 clinical trial that enrolled healthy volunteers. Daewoong Pharmaceutical, the therapy’s developer, now plans to start a Phase 2 trial later this year. “We have established the basis for [Phase] 2 trials by confirming safety, tolerability and pharmacokinetic profile of DWN12088,” Sengho Jeon, CEO of Daewoong, said in a press release.…

You must be logged in to read/download the full post.